NEUP

Neuphoria is a pre-revenue clinical-stage CNS biopharma whose entire value rests on binary trial outcomes for BNC210 (Social Anxiety Disorder, PTSD) and a Merck-partnered α7 PAM program. The seductive-looking FY2025 numbers — $15.6M revenue and a net loss of just $0.4M (vs. -$15.5M and -$21.4M the two prior years) — are not the emergence of a real business. Management explicitly states the year was 'inclusive of the receipt of milestone payments associated with our research collaboration and licensing agreements'; strip that non-recurring cash and you have the same loss-making, product-less R&D shop as before. Revenue was blank in FY2023 and FY2024, so there is no durable top line to value on that 0.5x P/S.

The filing removes any ambiguity: under ASC 205-40 the company discloses substantial doubt about its ability to continue as a going concern within one year. It holds $14.2M cash against an accumulated deficit of $178.3M, has financed itself with ~$193M of lifetime equity issuance, and says it 'expect[s] to continue to incur net losses for the foreseeable future' with R&D and G&A both rising. Historical burn of $15–21M/year against $14.2M cash implies roughly a single year of runway — a near-certain dilutive raise into a $8M market cap, or worse. The ASX delisting in 2023 and the 99.9% collapse in share count (a deep reverse split leaving just 2.36M shares) underline the financing distress and the fragility of the equity.